The double anticancer and cardioprotective effect of anti-IL-1ß drugs let raise the hypothesis that combination of an anti-IL1ß drug with an anti-cancer therapy will allow to decrease the dose of the primary anti-cancer drug and herewith related deleterious effects. Here, IL1B is linked to cancer.